-$0.65 EPS Expected for Nektar Therapeutics (NKTR) This Quarter

Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will announce earnings per share of ($0.65) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at ($0.52). Nektar Therapeutics posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year over year growth rate of 364.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 7th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of $3.57 per share for the current financial year, with EPS estimates ranging from $3.22 to $3.82. For the next financial year, analysts expect that the company will report earnings of ($0.98) per share, with EPS estimates ranging from ($2.69) to $4.42. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.07. The firm had revenue of $27.80 million during the quarter, compared to analyst estimates of $26.08 million. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business’s quarterly revenue was down 81.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.37 EPS.

NKTR has been the subject of a number of recent research reports. Cowen restated a “buy” rating and issued a $86.00 price objective on shares of Nektar Therapeutics in a report on Thursday, August 9th. ValuEngine upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. BidaskClub upgraded shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 14th. Piper Jaffray Companies set a $125.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 25th. Finally, Zacks Investment Research lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $79.55.

In other Nektar Therapeutics news, Director Dennis L. Winger sold 34,250 shares of the company’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the transaction, the director now directly owns 59,875 shares in the company, valued at approximately $3,628,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director R Scott Greer sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the transaction, the director now owns 140,333 shares of the company’s stock, valued at $9,457,040.87. The disclosure for this sale can be found here. Insiders have sold a total of 96,000 shares of company stock valued at $5,825,680 over the last quarter. 4.31% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its holdings in Nektar Therapeutics by 6.7% in the 2nd quarter. FMR LLC now owns 25,705,902 shares of the biopharmaceutical company’s stock worth $1,255,220,000 after purchasing an additional 1,608,834 shares in the last quarter. OppenheimerFunds Inc. raised its holdings in Nektar Therapeutics by 7.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 11,560,779 shares of the biopharmaceutical company’s stock worth $564,512,000 after purchasing an additional 845,257 shares in the last quarter. First Trust Advisors LP raised its holdings in Nektar Therapeutics by 176.2% in the 3rd quarter. First Trust Advisors LP now owns 2,068,900 shares of the biopharmaceutical company’s stock worth $126,120,000 after purchasing an additional 1,319,776 shares in the last quarter. Frontier Capital Management Co. LLC raised its holdings in Nektar Therapeutics by 18.8% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 1,298,286 shares of the biopharmaceutical company’s stock worth $79,144,000 after purchasing an additional 205,891 shares in the last quarter. Finally, Carillon Tower Advisers Inc. raised its holdings in Nektar Therapeutics by 41.2% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 1,017,300 shares of the biopharmaceutical company’s stock worth $49,674,000 after purchasing an additional 296,875 shares in the last quarter. Institutional investors and hedge funds own 92.72% of the company’s stock.

Shares of NKTR traded down $2.64 during mid-day trading on Thursday, reaching $35.31. The company’s stock had a trading volume of 4,322,822 shares, compared to its average volume of 3,121,603. The firm has a market cap of $6.22 billion, a price-to-earnings ratio of -64.20 and a beta of 2.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 19.55 and a current ratio of 19.67. Nektar Therapeutics has a 52 week low of $30.30 and a 52 week high of $111.36.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply